Role of noncoding RNAs as biomarker and therapeutic targets for liver fibrosis

Gene Expression

Volumn 16, Issue 4, 2015, Pages 155-162

  Teng, Kun Yu ^a   Ghoshal, Kalpana ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Liver fibrosis; Long noncoding RNAs (lncRNAs); MicroRNAs (miRNAs); Noncoding RNAs (ncRNAs)

Indexed keywords

LONG UNTRANSLATED RNA; LONG UNTRANSLATED RNA MATERNALLY EXPRESSED GENE 3 PROTEIN; MICRORNA; MICRORNA 101; MICRORNA 122; MICRORNA 181B; MICRORNA 21; MICRORNA 214 3P; MICRORNA 221; MICRORNA 222; MICRORNA 29A; MICRORNA 29B; MICRORNA 34A; MICRORNA 513 3P; MICRORNA 571; MICRORNA 652; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNTRANSLATED RNA; BIOLOGICAL MARKER;

APOPTOSIS; BIOACCUMULATION; CARCINOGENESIS; DOWN REGULATION; DRUG TARGETING; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FIBROGENESIS; GENE EXPRESSION; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; LIPID STORAGE; LIVER FIBROSIS; POSTTRANSCRIPTIONAL GENE SILENCING; REGULATORY MECHANISM; REVIEW; UPREGULATION; GENETICS; LIVER CIRRHOSIS; METABOLISM; PHYSIOLOGY;

BIOMARKERS; HUMANS; LIVER CIRRHOSIS; MICRORNAS; RNA, UNTRANSLATED;

EID: 84957701502     PISSN: 10522166     EISSN: None     Source Type: Journal    
DOI: 10.3727/105221615X14399878166078     Document Type: Review

References (67)

1. Crick F. Central dogma of molecular biology. Nature 1970; 227(5258):561-563.
2. Cech TR, Steitz JA. The noncoding RNA revolutiontrashing old rules to forge new ones. Cell 2014; 157(1): 77-94.
3. Moazed D. Small RNAs in transcriptional gene silencing and genome defence. Nature 2009; 457(7228):413-420.
4. Shi X, Sun M, Liu H, Yao Y, Song Y. Long non-coding RNAs: A new frontier in the study of human diseases. Cancer Lett 2013; 339(2):159-166.
5. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008; 9(2):102-114.
6. He L, Hannon GJ. MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5(7):522-531.
7. Batista PJ, Chang HY. Long noncoding RNAs: Cellular address codes in development and disease. Cell 2013; 152(6):1298-1307.
8. Yang L, Froberg JE, Lee JT. Long noncoding RNAs: Fresh perspectives into the RNA world. Trends Biochem Sci 2014; 39(1):35-43.
9. Kapranov P, Cheng J, Dike S, Nix DA, Duttagupta R, Willingham AT, et al. RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science 2007; 316(5830):1484-1488.
10. Wapinski O, Chang HY. Long noncoding RNAs and human disease. Trends Cell Biol 2011; 21(6):354-361.
11. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: Insights into functions. Nat Rev Genet 2009; 10(3): 155-159.
12. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115(2):209-218.
13. Friedman SL. Liver fibrosis - From bench to bedside. J Hepatol 2003; 38(Suppl 1):S38-53.
14. Luedde T, Schwabe RF. NF-kappaB in the liver - Linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2011; 8(2):108-118.
15. Wallace MC, Friedman SL. Hepatic fibrosis and the microenvironment: Fertile soil for hepatocellular carcinoma development. Gene Expr 2014; 16(2):77-84.
16. Friedman SL, Roll FJ, Boyles J, Bissell DM. Hepatic lipocytes: The principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci USA 1985; 82(24):8681-8685.
17. He Y, Huang C, Zhang SP, Sun X, Long XR, Li J. The potential of microRNAs in liver fibrosis. Cell Signal 2012; 24(12):2268-2272.
18. He Y, Wu YT, Huang C, Meng XM, Ma TT, Wu BM, et al. Inhibitory effects of long noncoding RNA MEG3 on hepatic stellate cells activation and liver fibrogenesis. Biochim Biophys Acta 2014; 1842(11):2204-2215.
19. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5(3):215-229.
20. Krichevsky AM, Gabriely G. miR-21: A small multi-faceted RNA. J Cell Mol Med 2009; 13(1):39-53.
21. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007; 133(2):647-658.
22. Noetel A, Kwiecinski M, Elfimova N, Huang J, Odenthal M. microRNA are central players in anti-and profibrotic gene regulation during liver fibrosis. Front Physiol 2012; 3:49.
23. Davis BN, Hilyard AC, Lagna G, Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature 2008; 454(7200):56-61.
24. Zhong X, Chung AC, Chen HY, Meng XM, Lan HY. Smad3-mediated upregulation of miR-21 promotes renal fibrosis. J Am Soc Nephrol 2011; 22(9):1668-1681.
25. Zhang Z, Zha Y, Hu W, Huang Z, Gao Z, Zang Y, et al. The autoregulatory feedback loop of microRNA-21/programmed cell death protein 4/activation protein-1 (MiR-21/PDCD4/ AP-1) as a driving force for hepatic fibrosis development. J Biol Chem 2013; 288(52):37082-37093.
26. Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH, et al. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 2000; 6(6):1365-1375.
27. Massague J, Chen YG. Controlling TGF-beta signaling. Genes Dev 2000; 14(6):627-644.
28. le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A, et al. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J 2007; 26(15):3699-3708.
29. Ogawa T, Enomoto M, Fujii H, Sekiya Y, Yoshizato K, Ikeda K, et al. MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. Gut 2012; 61(11):1600-1609.
30. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78(1): 59-66.
31. Ji J, Yamashita T, Wang XW. Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma. Cell Biosci 2011; 1(1):4.
32. Wang B, Hsu SH, Majumder S, Kutay H, Huang W, Jacob ST, et al. TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene 2010; 29(12):1787-1797.
33. Wang B, Li W, Guo K, Xiao Y, Wang Y, Fan J. miR-181b promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients. Biochem Biophys Res Commun 2012; 421(1):4-8.
34. Kriegel AJ, Liu Y, Fang Y, Ding X, Liang M. The miR-29 family: Genomics, cell biology, and relevance to renal and cardiovascular injury. Physiol Genomics 2012; 44(4): 237-244.
35. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 2008; 105(35):13027-13032.
36. Roderburg C, Urban GW, Bettermann K, Vucur M, Zimmermann H, Schmidt S, et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology 2011; 53(1):209-218.
37. Kwiecinski M, Noetel A, Elfimova N, Trebicka J, Schievenbusch S, Strack I, et al. Hepatocyte growth factor (HGF) inhibits collagen I and IV synthesis in hepatic stellate cells by miRNA-29 induction. PLoS One 2011; 6(9):e24568.
38. Zhang Y, Wu L, Wang Y, Zhang M, Li L, Zhu D, et al. Protective role of estrogen-induced miRNA-29 expression in carbon tetrachloride-induced mouse liver injury. J Biol Chem 2012; 287(18):14851-14862.
39. Kwiecinski M, Elfimova N, Noetel A, Tox U, Steffen HM, Hacker U, et al. Expression of platelet-derived growth factor-C and insulin-like growth factor I in hepatic stellate cells is inhibited by miR-29. Lab Invest 2012; 92(7):978-987.
40. Zheng J, Wu C, Lin Z, Guo Y, Shi L, Dong P, et al. Curcumin up-regulates phosphatase and tensin homologue deleted on chromosome 10 through microRNA-mediated control of DNA methylation - A novel mechanism suppressing liver fibrosis. FEBS J 2014; 281(1):88-103.
41. Liu JJ, Lin XJ, Yang XJ, Zhou L, He S, Zhuang SM, et al. A novel AP-1/miR-101 regulatory feedback loop and its implication in the migration and invasion of hepatoma cells. Nucleic Acids Res 2014; 42(19):12041-12051.
42. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008; 322(5908):1695-1699.
43. Wang L, Zhang X, Jia LT, Hu SJ, Zhao J, Yang JD, et al. c-Myc-mediated epigenetic silencing of MicroRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma. Hepatology 2014; 59(5): 1850-1863.
44. Botella LM, Sanz-Rodriguez F, Komi Y, Fernandez LA, Varela E, Garrido-Martin EM, et al. TGF-beta regulates the expression of transcription factor KLF6 and its splice variants and promotes co-operative transactivation of common target genes through a Smad3-Sp1-KLF6 interaction. Biochem J 2009; 419(2):485-495.
45. Tu X, Zhang H, Zhang J, Zhao S, Zheng X, Zhang Z, et al. MicroRNA-101 suppresses liver fibrosis by targeting the TGFbeta signalling pathway. J Pathol 2014; 234(1):46-59.
46. Hsu SH, Wang B, Kota J, Yu J, Costinean S, Kutay H, et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 2012; 122(8):2871-2883.
47. Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R, et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 2012; 122(8):2884-2897.
48. Li J, Ghazwani M, Zhang Y, Lu J, Li J, Fan J, et al. miR-122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression. J Hepatol 2013; 58(3):522-528.
49. Iizuka M, Ogawa T, Enomoto M, Motoyama H, Yoshizato K, Ikeda K, et al. Induction of microRNA-214-5p in human and rodent liver fibrosis. Fibrogenesis Tissue Repair 2012; 5(1):12.
50. Chen L, Charrier A, Zhou Y, Chen R, Yu B, Agarwal K, et al. Epigenetic regulation of connective tissue growth factor by MicroRNA-214 delivery in exosomes from mouse or human hepatic stellate cells. Hepatology 2014; 59(3):1118-1129.
51. Kodama T, Takehara T, Hikita H, Shimizu S, Shigekawa M, Tsunematsu H, et al. Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice. J Clin Invest 2011; 121(8):3343-3356.
52. Rachfal AW, Brigstock DR. Connective tissue growth factor (CTGF/CCN2) in hepatic fibrosis. Hepatol Res 2003; 26(1):1-9.
53. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9(6):654-659.
54. Braconi C, Kogure T, Valeri N, Huang N, Nuovo G, Costinean S, et al. microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene 2011; 30(47):4750-4756.
55. Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol 2013; 10(9):542-552.
56. Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: A new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 2010; 101(10):2087-2092.
57. Li WQ, Chen C, Xu MD, Guo J, Li YM, Xia QM, et al. The rno-miR-34 family is upregulated and targets ACSL1 in dimethylnitrosamine-induced hepatic fibrosis in rats. FEBS J 2011; 278(9):1522-1532.
58. Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 2011; 6(8):e23937.
59. Roderburg C, Mollnow T, Bongaerts B, Elfimova N, Vargas Cardenas D, Berger K, et al. Micro-RNA profiling in human serum reveals compartment-specific roles of miR-571 and miR-652 in liver cirrhosis. PLoS One 2012; 7(3):e32999.
60. Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, Jia WH, et al. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010; 51(3):836-8345.
61. He X, Xie J, Zhang D, Su Q, Sai X, Bai R, et al. Recombinant adeno-associated virus-mediated inhibition of miRNA-21 protects mice against the lethal schistosome infection by repressing both IL-13 and transforming growth factor beta1 pathways. Hepatology 2015; 61(6):2008-2017.
62. Lakner AM, Steuerwald NM, Walling TL, Ghosh S, Li T, McKillop IH, et al. Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis. Hepatology 2012; 56(1):300-310.
63. Clark MB, Johnston RL, Inostroza-Ponta M, Fox AH, Fortini E, Moscato P, et al. Genome-wide analysis of long noncoding RNA stability. Genome Res 2012; 22(5):885-898.
64. Panzitt K, Tschernatsch MM, Guelly C, Moustafa T, Stradner M, Strohmaier HM, et al. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 2007; 132(1):330-342.
65. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013; 368(18):1685-1694.
66. Hsu SH, Yu B, Wang X, Lu Y, Schmidt CR, Lee RJ, et al. Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor. Nanomedicine 2013; 9(8):1169-1180.
67. Zhang M, Zhou X, Wang B, Yung BC, Lee LJ, Ghoshal K, et al. Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma. J Control Release 2013; 168(3):251-261.